Pillar 2 - Breast Cancer, page-123

This abstract was released on the 27th of April. I have contacted the lead author and they are expecting the full text PDF to be available later this year.

Briefly, they demonstrated that the FTO inhibitors MA2 and FB23-2 (~49- and ~18-fold less potent than Bisantrene, respectively) was effective at inhibiting cell proliferation in brain metastatic patient derived xenograft mouse models (complex mice models that use cancer cells from real patients). The abstract suggests that they used multiple PDX and 3D organoid BrM models to determine efficacy. Of course, I will post data as it becomes available.

Importantly, the study used cells obtained from ER+ resistant breast cancer patients and transplanted them into mice.

RAC will initiate an open label PII study including ER+ metastatic breast cancer patients who are resistant to other therapies, which based on data obtained from the compelling final preclinical breast cancer results will be similar to the group that was used to collect cancer cells in this study.

1 https://academic.oup.com/bjs/article/108/Supplement_1/znab117.028/6255842